Literature DB >> 22846728

Whole-genome and whole-exome sequencing in hereditary cancer: impact on genetic testing and counseling.

Julianne M O'Daniel1, Kristy Lee.   

Abstract

The incorporation of whole-genome and whole-exome sequencing into clinical practice will undoubtedly change the way genetic counselors and other clinicians approach genetic testing. Enabling the analysis of essentially all human genes in one comprehensive test, this new technology can result in reduced testing cost and time to diagnosis. Another consequence of this broad scope, however, is the increased amount, complexity, and variety of results a clinician may need to discuss with a patient. The purpose of this article is to review the technology and outline some of the benefits and challenges of whole-genome and whole-exome sequencing in hereditary cancer practice.

Entities:  

Mesh:

Year:  2012        PMID: 22846728     DOI: 10.1097/PPO.0b013e318262467e

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  14 in total

Review 1.  Incidental findings from clinical genome-wide sequencing: a review.

Authors:  Z Lohn; S Adam; P H Birch; J M Friedman
Journal:  J Genet Couns       Date:  2013-05-26       Impact factor: 2.537

2.  The incorporation of predictive genomic testing into genetic counseling programs.

Authors:  Ryan Noss; Rachel Mills; Nancy Callanan
Journal:  J Genet Couns       Date:  2014-03-02       Impact factor: 2.537

3.  Pediatric Whole Exome Sequencing: an Assessment of Parents' Perceived and Actual Understanding.

Authors:  Leandra K Tolusso; Kathleen Collins; Xue Zhang; Jennifer R Holle; C Alexander Valencia; Melanie F Myers
Journal:  J Genet Couns       Date:  2016-12-16       Impact factor: 2.537

4.  Challenges to clinical utilization of hereditary cancer gene panel testing: perspectives from the front lines.

Authors:  Rebecca K Marcus; Jennifer L Geurts; Jessica A Grzybowski; Kiran K Turaga; T Clark Gamblin; Kimberly A Strong; Fabian M Johnston
Journal:  Fam Cancer       Date:  2015-12       Impact factor: 2.375

5.  Germline Analysis from Tumor-Germline Sequencing Dyads to Identify Clinically Actionable Secondary Findings.

Authors:  Bryce A Seifert; Julianne M O'Daniel; Krunal Amin; Daniel S Marchuk; Nirali M Patel; Joel S Parker; Alan P Hoyle; Lisle E Mose; Andrew Marron; Michele C Hayward; Christopher Bizon; Kirk C Wilhelmsen; James P Evans; H Shelton Earp; Norman E Sharpless; D Neil Hayes; Jonathan S Berg
Journal:  Clin Cancer Res       Date:  2016-04-15       Impact factor: 12.531

6.  Genetic counselors' views and experiences with the clinical integration of genome sequencing.

Authors:  Kalotina Machini; Jessica Douglas; Alicia Braxton; Judith Tsipis; Kate Kramer
Journal:  J Genet Couns       Date:  2014-03-28       Impact factor: 2.537

7.  Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study.

Authors:  Xin Niu; Laura M Amendola; Ragan Hart; Caroline S Bennette; Patrick Heagerty; Martha Horike-Pyne; Susan B Trinidad; Elisabeth A Rosenthal; Bryan Comstock; Chris Nefcy; Fuki M Hisama; Robin L Bennett; William M Grady; Carlos J Gallego; Peter Tarczy-Hornoch; Stephanie M Fullerton; Wylie Burke; Dean A Regier; Michael O Dorschner; Brian H Shirts; Peggy D Robertson; Deborah A Nickerson; Donald L Patrick; Gail P Jarvik; David L Veenstra
Journal:  Contemp Clin Trials       Date:  2019-08-07       Impact factor: 2.226

8.  PTEN germline mutations in patients initially tested for other hereditary cancer syndromes: would use of risk assessment tools reduce genetic testing?

Authors:  Jessica L Mester; Rebekah A Moore; Charis Eng
Journal:  Oncologist       Date:  2013-09-13

9.  Systemic treatment for hereditary cancers: a 2012 update.

Authors:  Evgeny N Imyanitov; Tomasz Byrski
Journal:  Hered Cancer Clin Pract       Date:  2013-04-01       Impact factor: 2.857

10.  Secondary findings and carrier test frequencies in a large multiethnic sample.

Authors:  Tomasz Gambin; Shalini N Jhangiani; Jennifer E Below; Ian M Campbell; Wojciech Wiszniewski; Donna M Muzny; Jeffrey Staples; Alanna C Morrison; Matthew N Bainbridge; Samantha Penney; Amy L McGuire; Richard A Gibbs; James R Lupski; Eric Boerwinkle
Journal:  Genome Med       Date:  2015-06-13       Impact factor: 15.266

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.